Latest Commercialisation News

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.

Blue Star Helium has completed flow testing at its Mula well in Colorado, revealing robust gas flow rates and a helium concentration above regional norms, bolstering the asset’s commercial promise.

Conrad Asia Energy has advanced its position in Indonesia’s natural gas sector with a major gas sales agreement and increased ownership in the Duyung PSC. The company also completed a A$9 million capital raise to fund upcoming development milestones.

Decidr AI Industries reported an 82% revenue jump in its AI platform during Q4 FY25, launched AI Mentors with The Growth Faculty, and divested its 13Seeds business to sharpen focus on AI innovation.

Micro-X has landed a significant supply agreement with a top US healthcare provider for its Rover Plus mobile X-ray units, while progressing clinical trials and development milestones for its innovative CT imaging products.

Volt Group reported a 15% decline in Q2 FY25 revenue due to customer order timing delays but secured new Wescone orders pointing to a strong Q3 recovery. Meanwhile, EcoQuip and ATEN projects advanced with promising demonstrations and feasibility studies.

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.

Carnegie Clean Energy has made significant strides in advancing its wave energy technologies, signing key MOUs and achieving critical milestones in the ACHIEVE Programme during the June 2025 quarter.

Acrux Limited has secured a decade-long licensing agreement with Servacure to commercialise its FDA-approved Dapsone 5% Gel in Saudi Arabia, marking a strategic step in its global expansion.

Lithium Universe Limited has secured global rights to a breakthrough solar panel recycling technology that promises to unlock vast reserves of critical minerals, while advancing its Québec lithium refinery with robust financials and strategic partnerships.

Nyrada reports successful completion of five cohorts in its Phase I trial of Xolatryp with no safety concerns, alongside compelling preclinical neuro- and cardioprotective data. A Phase IIa trial targeting heart attack patients is slated for early 2026.